Aktienanalyse zu Medpace Holdings Inc (MEDP)MEDPMedpace Holdings Inc

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Medpace Holdings Inc is a good buy right now due to its strong financial performance and positive market outlook. The current price is $669.20, with a recent RSI of 76.68 indicating strong momentum. Additionally, the company reported record new business awards in Q3 2026, reflecting robust client demand. The forward P/E ratio is 31.95, suggesting growth potential, while the gross margin stands at 30.35%. However, a risk to consider is the CEO's recent sale of shares, which could raise concerns among investors, although it represents only 3% of his holdings.

7 analysts cover MEDP: 1 rate it Buy, 6 Hold and 0 Sell. The average price target is 569.17.